• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real-world ERNEST-2 registry.

作者信息

Guglielmelli Paola, Ghirardi Arianna, Carobbio Alessandra, Masciulli Arianna, Morrone Lucrezia, Mora Barbara, Rumi Elisa, Triguero Ana, Finazzi Maria C, Pettersson Helna, Boldrini Valentina, Vanni Daniele, Rambaldi Alessandro, Passamonti Francesco, Alvarez-Larràn Alberto, Andreasson Bjorn, Vannucchi Alessandro M, Barbui Tiziano

机构信息

Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi University of Florence Florence Italy.

FROM Research Foundation, Papa Giovanni XXIII Hospital Bergamo Italy.

出版信息

Hemasphere. 2025 Jan 31;9(2):e70072. doi: 10.1002/hem3.70072. eCollection 2025 Feb.

DOI:10.1002/hem3.70072
PMID:39897086
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11783225/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ed2/11783225/8e39945495d0/HEM3-9-e70072-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ed2/11783225/8e39945495d0/HEM3-9-e70072-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ed2/11783225/8e39945495d0/HEM3-9-e70072-g001.jpg

相似文献

1
Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real-world ERNEST-2 registry.初诊时血细胞减少的明显原发性骨髓纤维化：前瞻性真实世界ERNEST-2注册研究的结果分析
Hemasphere. 2025 Jan 31;9(2):e70072. doi: 10.1002/hem3.70072. eCollection 2025 Feb.
2
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.Ruxolitinib 在血细胞减少性骨髓纤维化中的疗效、毒性、停药和结局。
Cancer. 2023 Jun 1;129(11):1704-1713. doi: 10.1002/cncr.34722. Epub 2023 Mar 18.
3
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis.血细胞减少表型在纤维化前期与明显原发性骨髓纤维化中的差异预后影响
Blood Cancer J. 2022 Aug 12;12(8):116. doi: 10.1038/s41408-022-00713-6.
4
Cytopenic myelofibrosis: prevalence, relevance, and treatment.细胞减少性骨髓纤维化：患病率、相关性和治疗。
Expert Opin Pharmacother. 2023 Jun;24(8):901-912. doi: 10.1080/14656566.2023.2203318. Epub 2023 Apr 17.
5
New approaches to tackle cytopenic myelofibrosis.应对细胞减少性骨髓纤维化的新方法。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):235-244. doi: 10.1182/hematology.2022000340.
6
SOHO State of the Art Updates and Next Questions | Updates on Myelofibrosis With Cytopenia.SOHO最新技术进展与后续问题 | 血细胞减少的骨髓纤维化进展
Clin Lymphoma Myeloma Leuk. 2025 May;25(5):293-303. doi: 10.1016/j.clml.2024.09.002. Epub 2024 Sep 21.
7
Comprehensive Characterization of Overt Myelofibrosis in an Asian Cohort: Phenotype, Mutation Landscape and Discordance Among Scoring Systems.
Hematol Oncol. 2025 Jan;43(1):e70040. doi: 10.1002/hon.70040.
8
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study.芦可替尼对真实世界中骨髓纤维化患者生存的影响：ERNEST研究更新
Blood Adv. 2022 Jan 25;6(2):373-375. doi: 10.1182/bloodadvances.2021006006.
9
MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients.莫雷利夫 - 真实世界数据支持莫洛替尼作为治疗细胞减少性骨髓纤维化患者的安全有效治疗选择的潜力。
Ann Hematol. 2024 Oct;103(10):4065-4077. doi: 10.1007/s00277-024-05908-4. Epub 2024 Jul 29.
10
Biological drivers of clinical phenotype in myelofibrosis.骨髓纤维化临床表型的生物学驱动因素。
Leukemia. 2023 Feb;37(2):255-264. doi: 10.1038/s41375-022-01767-y. Epub 2022 Nov 24.

本文引用的文献

1
Incidence of blast phase in myelofibrosis according to anemia severity.根据贫血严重程度划分的骨髓纤维化急变期发生率。
EJHaem. 2023 Jul 17;4(3):679-689. doi: 10.1002/jha2.745. eCollection 2023 Aug.
2
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.Ruxolitinib 在血细胞减少性骨髓纤维化中的疗效、毒性、停药和结局。
Cancer. 2023 Jun 1;129(11):1704-1713. doi: 10.1002/cncr.34722. Epub 2023 Mar 18.
3
Molecular prognostication in Ph-negative MPNs in 2022.2022 年 Ph 阴性 MPN 中的分子预后。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):225-234. doi: 10.1182/hematology.2022000339.
4
New approaches to tackle cytopenic myelofibrosis.应对细胞减少性骨髓纤维化的新方法。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):235-244. doi: 10.1182/hematology.2022000340.
5
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis.血细胞减少表型在纤维化前期与明显原发性骨髓纤维化中的差异预后影响
Blood Cancer J. 2022 Aug 12;12(8):116. doi: 10.1038/s41408-022-00713-6.
6
Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported.骨髓纤维化中的严重血小板减少症比先前报道的更为普遍。
Leuk Res. 2020 Apr;91:106338. doi: 10.1016/j.leukres.2020.106338. Epub 2020 Feb 26.
7
The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.骨髓纤维化中的骨髓耗竭表型：临床相关性和治疗意义。
Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):415-421. doi: 10.1016/j.clml.2020.01.008. Epub 2020 Feb 26.
8
Myelofibrosis Treatment Algorithm 2018.2018 年骨髓纤维化治疗算法。
Blood Cancer J. 2018 Jul 31;8(8):72. doi: 10.1038/s41408-018-0109-0.
9
U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions.原发性骨髓纤维化中的U2AF1突变类型：表型和预后差异
Leukemia. 2018 Oct;32(10):2274-2278. doi: 10.1038/s41375-018-0078-0. Epub 2018 Feb 27.
10
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.MIPSS70：原发性骨髓纤维化移植年龄患者的突变增强国际预后评分系统。
J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9.